Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 325 of 1475 entries
View as:

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

Phase: N/A Priority: Normal
NCT ID: NCT00254293 Org: User:
Start: 01/31/06 End: 07/31/12 Due: 07/31/13

Phase III Acute Coronary Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00831441 Org: User:
Start: 03/31/09 End: 03/31/11 Due: 03/31/12

Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

Phase: N/A Priority: Normal
NCT ID: NCT01540461 Org: User:
Start: 03/31/12 End: 11/30/13 Due: 11/30/14

Expanded Access for Relatlimab

Phase: N/A Priority: Normal
NCT ID: NCT05170659 Org: User:
Start: - End: - Due: -

Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa

Phase: N/A Priority: Normal
NCT ID: NCT02598466 Org: User:
Start: 07/31/15 End: 01/31/16 Due: 01/31/17

MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00207103 Org: User:
Start: 09/30/04 End: 09/30/08 Due: 09/30/09

A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV

Phase: N/A Priority: Normal
NCT ID: NCT00002358 Org: User:
Start: - End: - Due: -

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00570752 Org: User:
Start: 12/31/08 End: 12/31/10 Due: 12/31/11

A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05599685 Org: User:
Start: 10/19/22 End: 06/30/27 Due: 06/30/28

A Lactation Study in Women Receiving Treatment With Ozanimod

Phase: N/A Priority: Normal
NCT ID: NCT06181630 Org: User:
Start: 06/17/25 End: 12/16/26 Due: 12/16/27

Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01653470 Org: User:
Start: 10/12/12 End: 05/08/17 Due: 05/08/18

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT06003426 Org: User:
Start: 09/14/23 End: 10/26/26 Due: 10/26/27

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT05076175 Org: User:
Start: 05/30/22 End: 08/14/31 Due: 08/14/32

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Phase: N/A Priority: Normal
NCT ID: NCT02667587 Org: User:
Start: 05/09/16 End: 04/09/24 Due: 04/09/25

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05002569 Org: User:
Start: 10/19/21 End: 04/02/25 Due: 04/02/26

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02341638 Org: User:
Start: 09/30/14 End: 09/30/15 Due: 09/30/16

A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)

Phase: N/A Priority: Normal
NCT ID: NCT06701513 Org: User:
Start: 01/29/25 End: 04/30/28 Due: 04/30/29

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

Phase: N/A Priority: Normal
NCT ID: NCT01750580 Org: User:
Start: 12/31/12 End: 04/30/15 Due: 04/30/16

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

Phase: N/A Priority: Normal
NCT ID: NCT06672523 Org: User:
Start: 03/24/25 End: 04/20/26 Due: 04/20/27

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects

Phase: N/A Priority: Normal
NCT ID: NCT03541564 Org: User:
Start: 05/30/18 End: 09/04/18 Due: 09/04/19

An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT03252587 Org: User:
Start: 09/21/17 End: 10/28/21 Due: 10/28/22

YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey

Phase: N/A Priority: Normal
NCT ID: NCT02224768 Org: User:
Start: 07/31/15 End: 11/30/15 Due: 11/30/16

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT06088264 Org: User:
Start: 10/31/23 End: 12/22/23 Due: 12/22/24

A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Phase: N/A Priority: Normal
NCT ID: NCT05665192 Org: User:
Start: 08/02/21 End: 07/24/23 Due: 07/24/24

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03195478 Org: User:
Start: 08/02/17 End: 01/05/24 Due: 01/05/25